Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引：34

作者：

Kita, Mariko ^{[1
]}

Fox, Robert J. ^{[2
]}

Phillips, J. Theodore ^{[3
]}

Hutchinson, Michael ^{[4
]}

Havrdova, Eva ^{[5
]}

Sarda, Sujata P. ^{[6
]}

Agarwal, Sonalee ^{[6
]}

Kong, Jessica ^{[6
]}

Zhang, Annie ^{[6
]}

Viglietta, Vissia ^{[6
]}

Sheikh, Sarah I. ^{[6
]}

Seidman, Emily ^{[7
]}

Dawson, Katherine T. ^{[6
]}

机构：

[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland

[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[6] Biogen Idec Inc, Cambridge, MA USA

[7] CircleSci, Tytherington, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 02期

关键词：

Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;

D O I：

10.1177/1352458513507818

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

引用

页码：253 / 257

页数：5

共 50 条

[1] Effects of BG-12 on quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study
Kita, M.
Fox, R. J.
Phillips, J. T.
Hutchinson, M.
Havrdova, E.
Sarda, S. P.
Kong, J.
Viglietta, V.
Sheikh, S. I.
Dawson, K. T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 254 - 254
[2] Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
Hutchinson, M.
Fox, R. J.
Miller, D.
Phillips, J. T.
Kita, M.
Havrdova, E.
Yang, M.
Zhang, R.
Novas, M.
Viglietta, V.
Dawson, K. T.
JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S106
[3] Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis) study
Hutchinson, M.
Fox, R. J.
Miller, D.
Phillips, J. T.
Kita, M.
Havrdova, E.
O'Gorman, J.
Yang, M.
Novas, M.
Viglietta, V.
Dawson, K. T.
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 355 - 355
[4] Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study
Kappos, Ludwig
Gold, Ralf
Arnold, Douglas L.
Bar-Or, Amit
Giovannoni, Gavin
Selmaj, Krzysztof
Sarda, Sujata P.
Agarwal, Sonalee
Zhang, Annie
Sheikh, Sarah I.
Seidman, Emily
Dawson, Katherine T.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (02) : 243 - 252
[5] EFFECTS OF BG-12 ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: FINDINGS FROM THE PHASE 3 CONFIRM STUDY
Kita, M.
Fox, R. J.
Phillips, J. T.
Hutchinson, M.
Havrdova, E.
Sarda, S. P.
Kong, J.
Viglietta, V.
Sheikh, S., I
Dawson, K. T.
VALUE IN HEALTH, 2012, 15 (07) : A556 - A556
[6] Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM
Havrdova, Eva
Hutchinson, Michael
Kurukulasuriya, Nuwan C.
Raghupathi, Kartik
Sweetser, Marianne T.
Dawson, Katherine T.
Gold, Ralf
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2145 - 2156
[7] Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
agarwal, Sonalee
Kappos, Ludwig
Gold, Ralf
Arnold, Douglas
Bar-Or, Amit
Giovannoni, Gavin
Selmaj, Krzysztof
Kong, Jessica
Sheikh, Sarah
Dawson, Katherine
NEUROLOGY, 2012, 78
[8] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study
Hutchinson, Michael
Fox, Robert J.
Miller, David H.
Phillips, J. Theodore
Kita, Mariko
Havrdova, Eva
O'Gorman, John
Zhang, Ray
Novas, Mark
Viglietta, Vissia
Dawson, Katherine T.
JOURNAL OF NEUROLOGY, 2013, 260 (09) : 2286 - 2296
[9] Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis
Kappos, Ludwig
Giovannoni, Gavin
Gold, Ralf
Fox, Robert
Phillips, J. Theodore
Hotermans, Christophe
Zhang, Annie
Viglietta, Vissia
Miller, David
NEUROLOGY, 2013, 80
[10] Efficacy and Safety of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis in the Phase 3 CONFIRM Study
Hutchinson, M.
Fox, R. J.
Phillips, J. T.
Miller, D. H.
Havrdova, E.
Kita, M.
Yang, M.
Zhang, R.
Novas, M.
Sweetser, M. T.
Viglietta, V.
Dawson, K. T.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 683 - 683

← 1 2 3 4 5 →